Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência.
Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
Patients who experience an angioedema attack during treatment with angiotensin-converting enzyme inhibitors — a kind of medication for high blood pressure and heart failure — may safely switch to a ... Read more
Takhzyro (lanadelumab), a kallikrein inhibitor by Shire, has been approved in Europe for the routine prevention of hereditary angioedema (HAE) attacks in patients ages 12 and older, making it the first antibody available in ... Read more
Routine treatment with Shire‘s Takhzyro (lanadelumab) — given as a 300 mg dose every two weeks — significantly reduces the rate of acute attacks in hereditary angioedema (HAE) patients age 12 ... Read more
The U.S. Food and Drug Administration recently approved Shire’s Cinryze (C1 esterase inhibitor ) to help prevent angioedema attacks in children 6 and older who live with hereditary angioedema (HAE). ... Read more
The European Medicines Agency issued a positive opinion on BioCryst Pharmaceuticals’ application for orphan drug status of BCX7353 to treat hereditary angioedema (HAE). The European Commission is expected to adopt the ... Read more
A marketing authorization application for Lanadelumab, Shire‘s investigational therapy for hereditary angioedema (HAE), was recently cleared by the Swiss Agency for Therapeutic Products (Swissmedic), the company announced. Supported by data from ... Read more
The U.S. Food and Drug Administration plans a priority review of lanadelumab, Shire’s kallikrein inhibitor to prevent hereditary angioedema swelling attacks. Shire is asking for the therapy’s approval for patients aged ... Read more
The U.S. Food and Drug Administration (FDA) will review Shire’s application requesting that Cinryze (C1 esterase inhibitor ) be approved for the prevention of hereditary angioedema attacks in children 6 years and older. ... Read more
The application requesting that lanadelumab be reviewed with priority as a new treatment for the prevention of angioedema attacks has been accepted by Health Canada, the medicine’s manufacturer, Shire, announced. The New Drug ... Read more
The recently announced merger of BioCryst Pharmaceuticals and Idera Pharmaceuticals will strengthen the two companies’ focus on developing and commercializing treatments to serve patients with rare diseases, including angioedema, the companies ... Read more
Pin It on Pinterest